by Roger Longman
It’s not as if there are a lot of options.
Nearly all the meters on pharma's pipeline are reading critical. With licensing and M&A increasingly a series of high-priced auctions, Big Pharma is casting about, often desperately, for new business-development strategies. And one place they're beginning to look is corporate venture capital, traditionally a way to provide drug companies with a window on new technologies. But that means finding a way to break through the seemingly impenetrable wall between corporate venture investing and other corporate and research activities. Thus, companies have embarked on a number of different strategies, ranging from the traditional to the radically new and aggressive. Getting the equity investor and the asset-hungry pharma partner to co-exist peacefully has aroused plenty of both skepticism and confusion Nevertheless, there's still a promising way for drug companies to get value from start-ups beyond mere equity appreciation--investing de-prioritized drug candidates, not merely capital.
by Roger Longman
It’s not as if there are a lot of options.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Ordspono, a bispecific antibody newly approved in the EU to treat follicular lymphoma and diffuse large B-cell lymphoma, joins Libtayo in Regeneron’s growing oncology portfolio.
Nemluvio is a first-in-class IL-31 inhibitor that the US FDA approved for prurigo nodularis.
CEO Bill Anderson would not be drawn on whether the drug, currently approved for chronic kidney disease associated with type 2 diabetes, will hit a previous forecast of €3bn peak sales, but expansion into heart failure may make that figure look conservative.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.